ATE266655T1 - Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit - Google Patents
Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheitInfo
- Publication number
- ATE266655T1 ATE266655T1 AT00959835T AT00959835T ATE266655T1 AT E266655 T1 ATE266655 T1 AT E266655T1 AT 00959835 T AT00959835 T AT 00959835T AT 00959835 T AT00959835 T AT 00959835T AT E266655 T1 ATE266655 T1 AT E266655T1
- Authority
- AT
- Austria
- Prior art keywords
- dibenzopyrane
- treatment
- receptor antagonists
- glucocorticoid receptor
- subject disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38825199A | 1999-09-01 | 1999-09-01 | |
PCT/US2000/024234 WO2001016128A1 (en) | 1999-09-01 | 2000-09-01 | Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE266655T1 true ATE266655T1 (de) | 2004-05-15 |
Family
ID=23533319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00959835T ATE266655T1 (de) | 1999-09-01 | 2000-09-01 | Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1208095B1 (de) |
JP (1) | JP2003508393A (de) |
AR (1) | AR034096A1 (de) |
AT (1) | ATE266655T1 (de) |
AU (1) | AU7109000A (de) |
BR (1) | BR0009320A (de) |
CA (1) | CA2381239A1 (de) |
CO (1) | CO5180649A1 (de) |
DE (1) | DE60010722T2 (de) |
DK (1) | DK1208095T3 (de) |
ES (1) | ES2220529T3 (de) |
HK (1) | HK1047580B (de) |
MX (1) | MXPA02002110A (de) |
PT (1) | PT1208095E (de) |
WO (1) | WO2001016128A1 (de) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593480B2 (en) | 1999-09-01 | 2003-07-15 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
US7235662B2 (en) | 2003-06-11 | 2007-06-26 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
PE20100741A1 (es) | 2005-03-25 | 2010-11-25 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
PE20100737A1 (es) | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
TW200730498A (en) | 2005-12-20 | 2007-08-16 | Glaxo Group Ltd | Compounds |
EA200801997A1 (ru) | 2006-04-20 | 2009-04-28 | Глаксо Груп Лимитед | Новые соединения |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
TW200820977A (en) | 2006-08-08 | 2008-05-16 | Organon Nv | Use of glucocorticoid receptor antagonists for treatment of infectious conditions |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ,エルエルシー. | 5−リポキシゲナーゼ活性化タンパク質阻害剤 |
JP5502077B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
ES2566339T3 (es) | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
US9216221B2 (en) | 2008-11-07 | 2015-12-22 | University Of Sheffield | Medicament and method of diagnosis for treating subclinical Cushing's syndrome |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドGlaxo Group Limited | Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
EP2408769A1 (de) | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Als itk-inhibitoren verwendete pyrimidinderivate |
CN102439151A (zh) | 2009-03-19 | 2012-05-02 | 默沙东公司 | 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制 |
EP2408915A2 (de) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der genexpression von gata-bindungsprotein 3 (gata3) unter verwendung von sina (short interfering nucleic acid) |
US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012521764A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害 |
EP2411019A2 (de) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der signal transducer and activator of transcription 1 (stat1) gen-expression mittels sina (short interfering nucleic acid) |
WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
SG174581A1 (en) | 2009-03-27 | 2011-10-28 | Merck Sharp & Dohme | RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010122089A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
EP2421834A1 (de) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazol- und triazolcarbonsäureamide als inhibitoren des crac-kanals |
DK2899191T3 (da) | 2009-04-30 | 2017-11-13 | Glaxo Group Ltd | Oxazol-substituerede indazoler som pi3-kinaseinhibitorer |
JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
EP2507226A1 (de) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Neuartige verbindungen |
JP2013512880A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3−キナーゼ阻害剤としてのインダゾール誘導体 |
US20120272951A1 (en) | 2009-12-16 | 2012-11-01 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
JP5876051B2 (ja) | 2010-09-08 | 2016-03-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体 |
RS54286B1 (en) | 2010-09-08 | 2016-02-29 | Glaxosmithkline Intellectual Property Development Limited | POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドGlaxo Group Limited | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
EP2683716A1 (de) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazinderivate als syk-hemmer |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
MY184292A (en) | 2013-09-22 | 2021-03-30 | Sunshine Lake Pharma Co Ltd | Substituted aminopyrimidine compounds and methods of use |
CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
JP6475707B2 (ja) | 2013-10-17 | 2019-02-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
CA2943979A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
EP3347097B1 (de) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
EP3497100A1 (de) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemische verbindungen |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
EP3710006A4 (de) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | Substituierte heteroarylverbindungen und verfahren zur verwendung |
EP4125919A1 (de) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Cathepsinhemmer zur vorbeugung oder behandlung von virusinfektionen |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2091721B (en) * | 1980-10-20 | 1984-02-15 | Erba Farmitalia | 6-substituted 6h-dibezo(b,d)pyran derivatives and process for their preparation |
DE69904804T2 (de) * | 1998-02-13 | 2003-11-06 | Abbott Lab | Glucocorticoid selektive entzündungshemmende mittel |
-
2000
- 2000-08-30 CO CO00065017A patent/CO5180649A1/es not_active Application Discontinuation
- 2000-08-31 AR ARP000104550A patent/AR034096A1/es not_active Application Discontinuation
- 2000-09-01 WO PCT/US2000/024234 patent/WO2001016128A1/en active IP Right Grant
- 2000-09-01 BR BR0009320-3A patent/BR0009320A/pt not_active IP Right Cessation
- 2000-09-01 PT PT00959835T patent/PT1208095E/pt unknown
- 2000-09-01 ES ES00959835T patent/ES2220529T3/es not_active Expired - Lifetime
- 2000-09-01 JP JP2001519695A patent/JP2003508393A/ja not_active Withdrawn
- 2000-09-01 DK DK00959835T patent/DK1208095T3/da active
- 2000-09-01 AU AU71090/00A patent/AU7109000A/en not_active Abandoned
- 2000-09-01 EP EP00959835A patent/EP1208095B1/de not_active Expired - Lifetime
- 2000-09-01 DE DE60010722T patent/DE60010722T2/de not_active Expired - Lifetime
- 2000-09-01 AT AT00959835T patent/ATE266655T1/de not_active IP Right Cessation
- 2000-09-01 CA CA002381239A patent/CA2381239A1/en not_active Abandoned
- 2000-09-01 MX MXPA02002110A patent/MXPA02002110A/es not_active Application Discontinuation
-
2002
- 2002-10-17 HK HK02107584.5A patent/HK1047580B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2381239A1 (en) | 2001-03-08 |
EP1208095A1 (de) | 2002-05-29 |
AU7109000A (en) | 2001-03-26 |
HK1047580B (zh) | 2005-04-01 |
DE60010722D1 (de) | 2004-06-17 |
WO2001016128A1 (en) | 2001-03-08 |
ES2220529T3 (es) | 2004-12-16 |
BR0009320A (pt) | 2002-02-05 |
MXPA02002110A (es) | 2002-11-07 |
CO5180649A1 (es) | 2002-07-30 |
DK1208095T3 (da) | 2004-09-20 |
EP1208095B1 (de) | 2004-05-12 |
PT1208095E (pt) | 2004-09-30 |
DE60010722T2 (de) | 2005-05-12 |
JP2003508393A (ja) | 2003-03-04 |
HK1047580A1 (en) | 2003-02-28 |
AR034096A1 (es) | 2004-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE266655T1 (de) | Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit | |
ATE304530T1 (de) | Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen | |
ATE420083T1 (de) | Harnstoff-derivate als vanilloid-rezeptor- antagonisten für die schmerzbehandlung | |
ATE551340T1 (de) | Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten | |
DE60130675D1 (de) | Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose | |
DE60108754D1 (de) | Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
DE60204951D1 (de) | Ccr5 antagonisten verwendbar für die behandlung von aids | |
TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
ATE345331T1 (de) | Verbindungen verwendbar für die behandlung von entzündungskrankheiten | |
DZ2618A1 (fr) | Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie. | |
DE69927823T2 (de) | Hydrogel für die therapeutische behandlung von aneurysmas | |
ATE312117T1 (de) | Verbindungen für die behandlung von ischämie | |
ATE374196T1 (de) | Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen | |
DE60329123D1 (de) | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten | |
NO20034122D0 (no) | Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte | |
ATE346082T1 (de) | Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen | |
ATE286895T1 (de) | Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten | |
ATE396202T1 (de) | Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen | |
ATE502642T1 (de) | Kombinationen für die behandlung von immun- entzündlichen erkrankungen | |
NO20016246L (no) | Selektiv iGluR5 reseptorantagonist for behandling av migrene | |
DE60231107D1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
ATE260278T1 (de) | 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression | |
ATE300531T1 (de) | Isonipecotamide zur behandlung von integrin vermittelten störungen | |
DE60201440D1 (de) | Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1208095 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |